PMID- 38214356 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20240115 IS - 2212-3970 (Electronic) IS - 1574-8928 (Linking) VI - 19 IP - 2 DP - 2024 TI - The FJQR Has Synergistic Effect with Fluoropyrimidine in the Maintenance Treatment for HER-2 Negative Gastric Cancer. PG - 165-175 LID - 10.2174/1574892818666230522161742 [doi] AB - INTRODUCTION: Maintenance therapy aimed to strengthen the first-line chemotherapy and improve quality of life is needed for gastric cancer (GC). Currently, many clinical studies have confirmed the important role of fluoropyrimidine in the maintenance stage. Our team has created patented prescriptions "Fuzheng jiedu Quyu Method" recipe (FJQR), which was considered as an adjuvant therapeutic scheme (reduce toxicity and increase the efficacy of chemotherapy). This study aimed to evaluate the efficacy and safety of FJQR combined with fluoropyrimidine as a maintenance treatment in HER-2 negative GC patients. METHODS: We performed the analysis of 129 patients with HER-2 negative GC who entered the maintenance stage in our hospital and Tianjin Cancer Hospital between January 2018 and December 2020. Out of the 129 eligible patients, 64 were categorized into the maintenance treatment group with FJQR+fluoropyrimidine, and 65 patients were assigned to the control group if they received fluoropyrimidine alone. Capecitabine was orally 1000mg/m(2), Qd, half an hour after meals, and FGQR was 15g Bid after capecitabine. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS), overall remission rate (ORR), quality of Life (QOL), TCM syndrome and safety. RESULTS: The mPFS in the treatment group was significantly prolonged compared with the control group (6.3 vs. 5.0 months, p = 0.03), while the mOS was not substantially improved (11.4 vs. 10.5 months, p = 0.38). Gastrointestinal symptoms and pain became better in the treatment group. The number of distant metastatic organs, first-line chemotherapy cycles, and lymph node metastasis were independent risk predictors for PFS. Blood stasis syndrome may be the protective factor. In terms of safety, treatment-related adverse events (AEs) in the treatment group were relatively lighter, and the incidence of grade III-IV AEs could be significantly reduced. CONCLUSION: FJQR and fluoropyrimidine have synergistic effects as maintenance treatment in HER-2 negative GC, with good efficacy and safety. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Kong, Fanming AU - Kong F AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Zhao, Lu AU - Zhao L AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Wang, Na AU - Wang N AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Zhang, Dou AU - Zhang D AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Wang, Ziwei AU - Wang Z AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Mei, Qingyun AU - Mei Q AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Yu, Yongchao AU - Yu Y AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. FAU - Jia, Yingjie AU - Jia Y AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, 300193, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, 300193, Tianjin, China. LA - eng GR - 81403220/National Natural Science Foundation of China/ GR - 2018YFC1707400/National Key Research and Development (R&D) Plan/ PT - Journal Article PL - United Arab Emirates TA - Recent Pat Anticancer Drug Discov JT - Recent patents on anti-cancer drug discovery JID - 101266081 RN - 6804DJ8Z9U (Capecitabine) RN - 0 (fuzheng jiedu) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - *Stomach Neoplasms/drug therapy MH - Capecitabine/adverse effects MH - Quality of Life MH - Progression-Free Survival MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Drugs, Chinese Herbal OTO - NOTNLM OT - FJQR OT - Gastric cancer OT - HER-2. OT - fluoropyrimidine OT - maintenance therapy OT - traditional chinese medicine EDAT- 2024/01/12 12:43 MHDA- 2024/01/15 12:42 CRDT- 2024/01/12 07:55 PHST- 2022/11/18 00:00 [received] PHST- 2023/02/26 00:00 [revised] PHST- 2023/04/05 00:00 [accepted] PHST- 2024/01/15 12:42 [medline] PHST- 2024/01/12 12:43 [pubmed] PHST- 2024/01/12 07:55 [entrez] AID - PRA-EPUB-132003 [pii] AID - 10.2174/1574892818666230522161742 [doi] PST - ppublish SO - Recent Pat Anticancer Drug Discov. 2024;19(2):165-175. doi: 10.2174/1574892818666230522161742.